Xoma reported $-5976000 in Net Income for its fourth fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Net Income Change
Abbvie ABBV:US USD 2.47B 1.48B
Agenus AGEN:US USD -71093000 16.87M
Agios Pharmaceuticals AGIO:US USD 36.53M 118.27M
Ardelyx ARDX:US USD 10.7M 33.59M
Biomarin Pharmaceutical BMRN:US USD -249000 6.4M
Bluebird Bio BLUE:US USD -76520000 23.62M
Chimerix CMRX:US USD -20960000 262.32M
Eli Lilly And LLY:US USD 1.94B 486M
Emergent Biosolutions EBS:US USD -88000000 12.3M
Intercept Pharmaceuticals ICPT:US USD -20825000 288.28M
Life Technologies LIFE:US USD -7521000 5.72M
Macrogenics MGNX:US USD 12.8M 37.61M
Novartis NOVN:VX USD 1.47B 107M
Novartis NVS:US USD 1.47B 107M
Pfizer PFE:US USD 5B 3.61B
Prothena PRTA:US USD 6.35M 52.11M
Regeneron Pharmaceuticals REGN:US USD 1.2B 118.6M
Teva Pharmaceutical Industries TEVA:US USD -1222000000 1.28B
Xoma XOMA:US USD -5976000 1.8M
YTE INCY:US USD 28.46M 84.31M